Cooper Companies (The)
COO · What the business does, what can go wrong, and how options sellers approach it
What it does
The Cooper Companies makes medical devices through two segments: CooperVision and CooperSurgical.
CooperVision sells contact lenses, including daily disposable, monthly, multifocal, toric (for astigmatism) and specialty lenses. CooperSurgical focuses on women's health and fertility, with products used in clinics and hospitals, including equipment and consumables for IVF labs and contraception products.
How it makes money
CooperVision sells lenses through eye care professionals, retailers and online channels. Many lenses are replaced on a regular schedule, so sales tend to recur as long as wearers keep using the products.
CooperSurgical sells devices, consumables and diagnostic products to fertility clinics, hospitals and physician offices. Clinics that adopt a company's systems often keep buying the related supplies.
Why investors own it
- Contact lenses are a repeat-purchase category with steady underlying demand.
- Growing rates of nearsightedness and interest in myopia management create long-term opportunities.
- Fertility and women's health offer exposure to a different healthcare niche.
- Scale and relationships with eye care professionals can help in a market with a few large players.
What can go wrong
- Competition from larger and similar lens makers can pressure pricing and market share.
- Consumers may delay elective eye care or switch to cheaper lenses when budgets tighten.
- Fertility and women's health products can be affected by regulation, reimbursement changes and litigation.
- Acquisitions can bring integration problems and debt.
- Currency swings matter because the company sells around the world.
- Retail and distribution partners can change purchasing patterns.
What to watch
- Organic revenue growth in each segment
- Gross margin trends
- Daily disposable and specialty lens growth
- Myopia management product adoption
- Fertility procedure volumes
- Debt levels and capital allocation choices
- Regulatory decisions and product approvals
- Management guidance versus results
Options income angle
Options on COO are generally available across multiple expirations, though liquidity is usually thinner than for the largest healthcare names. Check bid-ask spreads and open interest before trading, especially for strikes far from the current price.
Implied volatility tends to rise ahead of quarterly earnings and guidance updates, and when demand trends or segment performance surprise the market. Sector-wide moves in medical devices can also matter.
One caution: a stock like this can gap sharply after earnings. A short call can cap upside if shares jump, and a short put can leave you owning shares after a steep drop. Premium collected does not remove that risk.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended October 31, 2025, filed December 5, 2025. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
The Cooper Companies' contact lens business, CooperVision, grew and became more profitable in fiscal 2025, while its women's health and fertility business, CooperSurgical, saw operating income fall sharply after write-offs and severance costs. Consolidated operating income was $682.9 million, down from $705.7 million. The company also carries a large debt load, including a $1,500.0 million term loan due December 17, 2026.
How the business did
- CooperVision net sales were $2,743.8 million versus $2,609.4 million. Toric and multifocal lenses (for astigmatism and age-related focusing problems) grew 7%, driven by Biofinity and MyDay. Sphere and other lenses grew 3%, helped by MiSight, while older hydrogel products declined. EMEA grew 8% and Asia Pacific was flat.
- CooperVision operating income rose to $729.6 million from $676.2 million, because sales growth outpaced expense growth.
- CooperSurgical net sales were $1,348.6 million versus $1,286.0 million, helped by Paragard contraceptive devices, genomic services, gamete services and the obp Surgical acquisition. Its operating income fell to $43.4 million from $118.3 million, mainly from inventory and long-lived asset write-offs, severance tied to workforce optimization initiatives, and higher amortization.
- Gross margin slipped to 66% from 67%. The effective tax rate rose to 33.8% from 32.6%.
- Operating cash flow was $796.1 million versus $709.3 million. The company repurchased 4.1 million shares for $290.1 million, after making none the prior year, and repaid part of its revolving credit.
Risks specific to this company
- Debt and refinancing. Outstanding borrowings were $2,456.3 million, including the $1,500.0 million 2021 Term Loan due December 17, 2026. The filing warns that debt covenants could restrict the company and that new financing may not be available on favorable terms.
- Sole-source materials. Key materials for silicone hydrogel lenses, including MyDay, Biofinity, Avaira and clariti, come from few or sole suppliers. Certain products are also approved for manufacture at only one site.
- Controls and systems. The company is midway through a multiyear ERP (enterprise software) rollout at both segments. It also disclosed a past material weakness, meaning a serious flaw in internal financial controls, in CooperSurgical's U.S. IT controls, which was remediated as of October 31, 2025.
- Customer consolidation and competition. Large key account customers and retail chains are a growing share of sales. CooperVision's largest rivals are Johnson & Johnson Vision Care, Alcon and Bausch Health, and direct-to-consumer online fulfillment is a further threat.
- Regulation of CooperSurgical. Risks include slower EU MDR and IVDR certification from a limited pool of notified bodies, possible FDA reclassification of its donor tissue and cord blood products, oversight of genetic tests, and restrictions on reproductive services.
- International and currency exposure. About half of net sales come from outside the United States. The largest currency exposures are the British pound, Euro and Japanese yen, and tariffs are flagged as uncertain.
What management is watching
- Management expects demand to keep shifting to single-use silicone hydrogel lenses and names clariti, MyDay and MyDay Energys as focus franchises. In the frequent replacement category, which covers monthly and two-week lenses, the focus is Biofinity and Avaira Vitality.
- Myopia management is a stated priority. MiSight 1 day has FDA approval, plus approval in China from the NMPA and in Japan from the MHLW, and management wants greater market penetration, including through acquisitions.
- R&D spending rose to $172.2 million from $155.1 million, with CooperVision and CooperSurgical each increasing project spend.
- Management says cash, operating cash flow and the revolving credit facility should cover needs for at least 12 months. The revolver has $1,338.4 million available, and interest payments of $98.7 million are projected for the twelve months ending October 31, 2026.
- The board raised the share repurchase authorization to $2.0 billion in September 2025, with $966.4 million remaining. Management also cites tariffs, inflation, exchange rates and supply chain disruption as uncertainties that have hurt results before.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended July 31, 2026, filed September 9, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Operating income for the third quarter ended July 31, 2026 was $222.0 million, up from $175.7 million a year earlier. Over the nine months it fell to $403.8 million from $542.5 million, because of a $272.0 million litigation expense, net of insurance recoveries, tied to CooperSurgical's 2023 embryo culture media recall. The company says it paid $306.8 million in August 2026 to settle substantially all of those claims.
How the business did
- Sales: CooperVision net sales were $717.0 million versus $718.4 million a year earlier. Toric and multifocal lenses (for astigmatism and age-related near vision) grew 1%, driven by MyDay, while sphere and other fell 2% on lower sales of older hydrogel lenses. The Americas fell 2% on reduced U.S. channel inventory, meaning customers drew down their stock. EMEA rose 6%, and Asia Pacific fell 10% on softness in Japan and China. For nine months CooperVision sales were $2,135.6 million, up 5%.
- CooperSurgical: Quarterly net sales were $349.2 million, up 2%, with fertility helped by genetic testing. It posted operating income of $41.1 million against a loss of $(4.2) million a year earlier, when it took inventory and asset write-offs on a product line exit. Those write-offs also explain why consolidated gross margin rose to 67% from 65%.
- Taxes: The effective tax rate was (114.5)% for the quarter. It is negative because the company booked a discrete (one-time) income tax benefit of $307.2 million after a UK tax authority examination closed in the company's favor.
- Cash and capital return: Nine-month operating cash flow was $785.4 million versus $548.2 million. The company repurchased 4.9 million shares for $339.1 million in the quarter, and 6.2 million shares for $444.7 million over nine months.
What management is watching
- Management gives no numeric guidance in this section. It says it is optimistic about long-term contact lens and health care markets and points to single-use silicone hydrogel lenses (clariti, MyDay) and myopia management (MiSight 1 day) as focus areas, while citing tariffs, inflation, currency and supply chain risks.
- The Board raised the share repurchase authorization by $1.0 billion in September 2026, to a total of $3.0 billion, with approximately $1.5 billion remaining at approval. Corporate expense rose on strategic review costs, though the filing does not describe the review.
- Working capital was $414.9 million versus $993.6 million at October 31, 2025, mainly because of more short-term debt. A $550.0 million term loan matures December 17, 2026. Outstanding revolver borrowings were $966.7 million, and the company says cash flow and credit availability should cover needs for the next 12 months and beyond.
- The company is appealing a UK tax tribunal decision on payroll tax tied to its 2014 Sauflon acquisition, with an estimated loss ranging from £0 to £71.7 million, plus accrued interest.
Follow COO in Kortex
The Kortex app shows COO's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.